DOCSLIB.ORG

Comprehensive Testing for Continuity of Care Endocrinology Reference Guide Access the Insight You Need

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive Testing for Continuity of Care Endocrinology Reference Guide Access the Insight You Need Comprehensive testing for continuity of care Endocrinology Reference Guide Access the insight you need Managing patients with endocrine disorders is complex. Having access to the right test for the right patient is key. With a legacy of expertise in endocrine laboratory diagnostics, Quest Diagnostics offers an extensive menu of laboratory tests across the spectrum of endocrine disorders. This test list highlights the extensive menu of laboratory diagnostic tests we offer, including highly specialized tests and those performed using highly specific and sensitive mass spectrometry detection. It is conveniently organized by glandular function or common endocrine disorder, making it easy for you to identify the tests you need to care for the patients you treat. Table of Contents Adrenal Disorders 1 Adrenocortical Function 1 Catecholamines 2 Congenital Adrenal Hyperplasia 2 Bone and Mineral Metabolism/Parathyroid Disorders 3 Bone and Mineral Metabolism 3 Parathyroid Metabolism 4 Cardiovascular Disorders 4 Dynamic Tests 5 Fluid, Electrolyte, Renal Disorders 6 Genetic Disorders 7 Growth Disorders 10 Hypothalamic and Pituitary Disorders 10 Metabolic (including Diabetes), Gastrointestinal, and Liver Disorders 11 Diabetes Mellitus and Diabetes Risk 11 Gastrointestinal and Liver Disorders 13 Obesity and Post Bariatric Surgery 13 Multiple Endocrine Neoplasia 14 Reproductive Disorders 15 Androgen and Reproductive Evaluation in Males 15 Gonadal Tumors 15 Polycystic Ovary Syndrome (PCOS) 16 Premature Ovarian Failure and Reproductive Evaluation in Females 16 Puberty (Delayed/Absent) 17 Puberty (Precocious) 17 Sexual Differentiation 18 Thyroid Disorders 19 Endocrinology Reference Guide Test Code Test Name Test Code Test Name Adrenal Disorders 402 DHEA Sulfate, Immunoassay 2 Adrenocortical Function 36168 Dihydrotestosterone, Free, Serum 2 6108 ABCD1 (Adrenoleukodystrophy) DNA 90567 Dihydrotestosterone, LC/MS/MS Sequencing Test1 6568(X) Estriol, Amniotic Fluid 211 ACTH, Plasma 34883(X) Estriol, LC/MS/MS, Serum2 4645(X) Adrenal Antibody Screen with Reflex to Titer 36707(X) Hirsutism Panel 22 229 Aldosterone, 24-Hour Urine2 Includes androstenedione, DHEA sulfate, and free and total testosterone. 17181 Aldosterone, LC/MS/MS2 15202 17-Hydroxycorticosteroids with Creatinine, 95084 Aldosterone, LC/MS/MS, Adrenal Vein2 24-Hour Urine 16845 Aldosterone/Plasma Renin Activity Ratio, 8352 17-Hydroxypregnenolone, LC/MS/MS2 LC/MS/MS2 17180 17-Hydroxyprogesterone, LC/MS/MS2 92208 3 -Androstanediol Glucuronide, ELISA3 α 17654(X) 17-Hydroxyprogesterone, Neonatal/Infant2 17182 Androstenedione, LC/MS/MS2 15201(X) 17-Ketosteroids with Creatinine, 24-Hour 812 Autoimmune Polyglandular Syndrome Urine (AIRE) Evaluation1 Detects point mutations, deletions, insertions, 37916(X) 21-Hydroxylase Antibody and rearrangements in AIRE. 92560 Li-Fraumeni Syndrome, TP53 Sequencing 2 6547(X) Corticosterone, LC/MS/MS2 and Deletion/Duplication 37355(X) Cortisol, Free and Cortisone, 24-Hour Urine2 814 NR0B1 (Adrenal Hypoplasia Congenita) DNA Sequencing Test1 37077(X) Cortisol, Free and Total, LC/MS/MS2 16846 Plasma Renin Activity, LC/MS/MS2 14534 Cortisol, Free, 24-Hour Urine2 31493(X) Pregnenolone, LC/MS/MS2 36423(X) Cortisol, Free, LC/MS/MS2 816 Primary Adrenal Insufficiency Evaluation1 11280(X) Cortisol, Free, LC/MS/MS, 24-Hour Urine2 Detects mutations (including point mutations, deletions, insertions, and rearrangements) in 90582 Cortisol, Free, LC/MS/MS, Second Void ABCD1, AIRE, and NR0B1. Urine2 17183 Progesterone, LC/MS/MS2 19897 Cortisol, LC/MS/MS, Saliva2 30740 Sex Hormone Binding Globulin 93020 Cortisol, LC/MS/MS, Saliva, 2 Samples2 36170 Testosterone, Free and Total, LC/MS/MS 18921 Cortisol, LC/MS/MS, Saliva, 4 Samples2 14966 Testosterone, Free, Bioavailable and Total, 11281 Cortisol, Total, LC/MS/MS2 LC/MS/MS 37554(X) Cortisone, 24-Hour Urine2 37073 Testosterone, Total and Free and Sex Hormone Binding Globulin 37098(X) Cortisone, Serum2 30543 11-Deoxycortisol, LC/MS/MS, Serum2 15983 Testosterone, Total, LC/MS/MS 90973 Deoxycorticosterone, LC/MS/MS2 19958 Testosterone, Total, Males (Adult), Immunoassay 29391(X) Dexamethasone2 19894 DHEA (Dehydroepiandrosterone), Unconjugated, LC/MS/MS2 1 Available from Athena Diagnostics Available from Quest Diagnostics Nichols Institute Test Code Test Name Test Code Test Name Catecholamines 14961(X) Metanephrines, Fractionated, LC/MS/MS, Random Urine2 (Panel components may be 39627(X) Catecholamines, Fractionated, 24-Hour ordered separately.) 2 Urine (Panel components may be ordered Includes creatinine (8459) and metanephrine, separately.) normetanephrine, and total metanephrines. Includes creatinine (8459), dopamine (17101X), epinephrine, norepinephrine, and total 37562 Norepinephrine, Plasma2 catecholamines (calculated). 889 Pheochromocytoma Evaluation1 39626(X) Catecholamines, Fractionated, and VMA, Detects mutations in VHL, RET and SDHB. 24-Hour Urine2 (Panel components may be ordered separately.) 10520(X) Pheochromocytoma Evaluation2 (Panel Includes creatinine (8459), dopamine components may be ordered separately.) (17101X), epinephrine, norepinephrine, total Includes creatinine (8459), total catecholamines catecholamines (calculated), and VMA (1710). (39627X), total metanephrines (14962X), and metanephrine/creatinine ratio (calculated). 314(X) Catecholamines, Fractionated, Plasma2 Includes dopamine, epinephrine, norepinephrine, 1710 VMA (Vanillylmandelic Acid), Random Urine2 and total catecholamines (calculated). 39517(X) VMA, 24-Hour Urine2 5244 Catecholamines, Fractionated, Random Urine2 (Panel components may be ordered Congenital Adrenal Hyperplasia separately.) Includes creatinine (375), dopamine (17101X), 91680 CAH (21-Hydroxylase Deficiency) Common 2 epinephrine, norepinephrine, and total Mutations, Fetal Cells catecholamines (calculated). 14755(X) CAH (21-Hydroxylase Deficiency) Common 16381 Catecholamines, Fractionated, Supine, Mutations2 Plasma2 Includes dopamine, epinephrine, norepinephrine, 16072(X) CAH (21-Hydroxylase Deficiency) Rare 2 and total catecholamines. Mutations 16382 Catecholamines, Fractionated, Upright, 15269(X) CAH Panel 1 (21-Hydroxylase vs Plasma2 11β-Hydroxylase Deficiency)2 Includes dopamine, epinephrine, norepinephrine, Includes androstenedione, 11-deoxycortisol, and total catecholamines. 17-hydroxyprogesterone, total cortisol, total testosterone, 11-deoxycortisol/cortisol ratio 16379 Chromogranin A, (calculated), and 17-hydroxyprogesterone/11- Electrochemiluminescence2 deoxycortisol ratio (calculated). 14762(X) Dopamine, Plasma2 15273(X) CAH Panel 3 (Aldosterone Synthase Deficiency) 17101(X) Dopamine, Random Urine2 Includes aldosterone, 11-deoxycortisol, 18-hydroxycorticosterone, 37560(X) Epinephrine, Plasma2 17-hydroxyprogesterone, 18-hydroxycorticosterone/aldosterone ratio 39527(X) Homovanillic Acid, 24-Hour Urine2 (calculated), and 17-hydroxyprogesterone/11- deoxycortisol ratio (calculated). 6346 Homovanillic Acid, Random Urine2 15274(X) CAH Panel 4 (17-Hydroxylase Deficiency in 14962(X) Metanephrines, Fractionated, LC/MS/MS, Females)2 24-Hour Urine2 Includes aldosterone, corticosterone, estradiol, Includes metanephrine, normetanephrine, and 17-hydroxyprogesterone, progesterone, total total metanephrines. cortisol, and progesterone/hydroxyprogesterone ratio (calculated). 19548 Metanephrines, Fractionated, LC/MS/MS, Plasma2 15276(X) CAH Panel 6 (StAR Deficiency)2 Includes metanephrine, normetanephrine, and Includes aldosterone, pregnenolone, total total metanephrines. cortisol, and unconjugated DHEA. Available from Athena Diagnostics Available from Quest Diagnostics Nichols Institute 2 Endocrinology Reference Guide Test Code Test Name Test Code Test Name 16978 CAH Panel 6C (Full Screen)2 874 Lipoid CAH (STAR) DNA Sequencing Test1 Includes androstenedione, Detects mutations (including point mutations, 11-deoxycortisol, 17-hydroxypregnenolone, deletions, insertions, and rearrangements) in the 17-hydroxyprogesterone, progesterone, total STAR gene. cortisol and unconjugated DHEA. 31493(X) Pregnenolone, LC/MS/MS2 15277(X) CAH Panel 7 (21-Hydroxylase Deficiency Therapeutic Monitoring)2 90397 Steroid Panel, 21-Hydroxylase Deficiency/ Includes androstenedione, Stress2 17-hydroxyprogesterone, and total testosterone. Includes androstenedione, 17-hydroxyprogesterone, and total cortisol. 15279(X) CAH Panel 8 (17-Hydroxylase Deficiency in Males)2 90392 Steroid Panel, Comprehensive2 Includes aldosterone, corticosterone, Includes androstenedione, corticosterone, 17-hydroxyprogesterone, progesterone, total cortisone, deoxycorticosterone, cortisol, total testosterone, and progesterone/17- 11-deoxycortisol, 18-hydroxycorticosterone, hydroxyprogesterone ratio (calculated). 17-hydroxypregnenolone, 17-hydroxyprogesterone, pregnenolone, 15280(X) CAH Panel 9 (3-β-Hydroxysteroid progesterone, total cortisol, total testosterone, Dehydrogenase Deficiency Profile) and unconjugated DHEA. Includes androstenedione, 17-hydroxypregnenolone, 90398 Steroid Panel, Congenital Adrenal 2 17-hydroxyprogesterone, total Hyperplasia (CAH) cortisol, unconjugated DHEA, Includes androstenedione, deoxycorticosterone, and 17-hydroxypregnenolone/17- 11-deoxycortisol, 17-hydroxypregnenolone, hydroxyprogesterone ratio (calculated), and 17-hydroxyprogesterone, progesterone, total DHEA/androstenedione ratio (calculated). cortisol, total testosterone, and unconjugated DHEA. 879 Congenital Adrenal Hyperplasia (CAH) 2 Evaluation1 90426 Steroid Panel, PCOS/CAH Differentiation Includes sequencing and deletion detection in Includes androstenedione,
Load more

Recommended publications
  • DIAGMOL Town, ZIPCODE :…………………………………………………… Director : Prof
    Mr. Mrs. (IN UPPER CASE, please) Name:……………………………………………………. Maiden Name:……………………………………. DMGL / Service de Médecine Génétique Centre d’accueil des prélèvements (CAP) First name :………………………………………………… Bâtiment des Laboratoires (BATLab), local 8D-0-850.1 Date of birth : ............ / ........... / …………… 4 rue Gabrielle-Perret-Gentil, 1211 Genève 14 Legal representative (for minors) : father mother Molecular and Genomic Diagnostics Laboratory Name/first name :…………………………………………… Street/N°:……………………………………………………… http://www.hug-ge.ch/feuilles-de-demande DIAGMOL Town, ZIPCODE :…………………………………………………… Director : Prof. Stylianos ANTONARAKIS Hospitalisation Unit: …………… Physician :…………………… Lab managers: N° EdS : …………………………………………………………… Dr J.-L. BLOUIN, Dr Th. NOUSPIKEL, Dr. M. GUIPPONI Invoice address: Patient Prescriptor Insurance [email protected], [email protected], [email protected] Type of case : Disease AI Accident Pregnancy Lab direct or results: Phone/FAX: +41 (0) 22 37 21 826 / 21 860 N° AVS (Mandatory for AI) : ………………………...................... Sample Entrance Center (CAP) : Phone +41 (0) 22 37 21 800 Insurance : ………………… Insured N° : ……………………… PHYSICIAN PHYSICIAN (NAME/First name - Street/N°- Town, ZIPCODE - Phone/FAX. IN UPPER CASES, PLEASE) COPY TO OTHER PHYSICIAN (NAME/First name - Street/N°- Town, ZIPCODE - Phone/FAX. IN UPPER CASES, PLEASE) « The laboratory is granted permission by the Physician/Patient to transmit copies of the report to other physicians» Opposition of the patient to the registration of this request results in the electronic patient record (DPI) of the HUG If the patient belongs to a family already known to the laboratory, please indicate index case NAME: CLINICAL INFORMATIONS given by the physician: Ethnic origins Father Mother Currently pregnant Date of last menses Number of weeks of amenorrhea SAMPLE(S) Most of our tests work from 4 ml of blood in EDTA (children <2 ans : 1 On every and single NAME First name ml : ok) or from purified DNA (some exceptions apply for some tests) tube.
    [Show full text]
  • Heterozygous ATP-Binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease
    bioRxiv preprint doi: https://doi.org/10.1101/780734; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Heterozygous ATP-binding Cassette Transporter G5 Gene Deficiency and Risk of Coronary Artery Disease Short title: Heterozygous ABCG5 deficiency and risk of CAD Akihiro Nomura*, MD PhD, Connor A. Emdin*, DPhil, Hong Hee Won, PhD, Gina M. Peloso, PhD, Pradeep Natarajan, MD, Diego Ardissino, MD, John Danesh, FRCP DPhil, Heribert Schunkert, MD, Adolfo Correa, MD PhD, Matthew J. Bown, MD FRCS, Nilesh J. Samani, MD FRCP, Jeanette Erdmann, PhD, Ruth McPherson, MD, Hugh Watkins, MD PhD, Danish Saleheen, MD, Roberto Elosua, MD PhD, Masa-aki Kawashiri, MD PhD, Hayato Tada, MD PhD, Namrata Gupta, PhD, Svati H. Shah, MD MHS, Daniel J. Rader, MD, Stacey Gabriel, PhD, Amit V. Khera*, MD, Sekar Kathiresan*, MD *: These authors contributed equally Address for correspondence: Sekar Kathiresan, MD Verve Therapeutics 26 Landsdowne Street, 1st Floor Cambridge, MA 02139 Email: [email protected] Phone: 617 603 0070 bioRxiv preprint doi: https://doi.org/10.1101/780734; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Background: Familial sitosterolemia is a rare, recessive Mendelian disorder characterized by hyperabsorption and decreased biliary excretion of dietary sterols.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • 1 ICR-Geneset Gene List
    ICR-geneset Gene List. IMAGE ID UniGene Locus Name Cluster 20115 Hs.62185 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 21738 21899 Hs.78353 SRPK2 SFRS protein kinase 2 21908 Hs.79133 CDH8 cadherin 8, type 2 22040 Hs.151738 MMP9 matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase) 22411 Hs.183 FY Duffy blood group 22731 Hs.1787 PHRET1 PH domain containing protein in retina 1 22859 Hs.356487 ESTs 22883 Hs.150926 FPGT fucose-1-phosphate guanylyltransferase 22918 Hs.346868 EBNA1BP2 EBNA1 binding protein 2 23012 Hs.158205 BLZF1 basic leucine zipper nuclear factor 1 (JEM-1) 23073 Hs.284244 FGF2 fibroblast growth factor 2 (basic) 23173 Hs.151051 MAPK10 mitogen-activated protein kinase 10 23185 Hs.289114 TNC tenascin C (hexabrachion) 23282 Hs.8024 IK IK cytokine, down-regulator of HLA II 23353 23431 Hs.50421 RB1CC1 RB1-inducible coiled-coil 1 23514 23548 Hs.71848 Human clone 23548 mRNA sequence 23629 Hs.135587 Human clone 23629 mRNA sequence 23658 Hs.265855 SETMAR SET domain and mariner transposase fusion gene 23676 Hs.100841 Homo sapiens clone 23676 mRNA sequence 23772 Hs.78788 LZTR1 leucine-zipper-like transcriptional regulator, 1 23776 Hs.75438 QDPR quinoid dihydropteridine reductase 23804 Hs.343586 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 23831 Hs.155247 ALDOC aldolase C, fructose-bisphosphate 23878 Hs.99902 OPCML opioid binding protein/cell adhesion molecule-like 23903 Hs.12526 Homo sapiens clone 23903 mRNA sequence 23932 Hs.368063 Human clone 23932 mRNA sequence 24004
    [Show full text]
  • The Effect of Statin Treatment on Intratumoral Cholesterol Levels and LDL Receptor Expression: a Window-Of-Opportunity Breast Ca
    Feldt et al. Cancer & Metabolism (2020) 8:25 https://doi.org/10.1186/s40170-020-00231-8 RESEARCH Open Access The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of- opportunity breast cancer trial Maria Feldt1,2* , Julien Menard1, Ann H. Rosendahl1,2, Barbara Lettiero1, Pär-Ola Bendahl1, Mattias Belting1,2,3 and Signe Borgquist1,4 Abstract Background: Deregulated lipid metabolism is common in cancer cells and the mevalonate pathway, which synthesizes cholesterol, is central in lipid metabolism. This study aimed to assess statin-induced changes of the intratumoral levels of cholesterol and the expression of the low-density lipoprotein receptor (LDLR) to enhance our understanding of the role of the mevalonate pathway in cancer cholesterol metabolism. Methods: This study is based on a phase II clinical trial designed as a window-of-opportunity trial including 50 breast cancer patients treated with 80 mg of atorvastatin/day for 2 weeks, between the time of diagnosis and breast surgery. Lipids were extracted from frozen tumor tissue sampled pre- and post-atorvastatin treatment. Intratumoral cholesterol levels were measured using a fluorometric quantitation assay. LDLR expression was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tumor tissue. Paired blood samples pre- and post- atorvastatin were analyzed for circulating low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1, and apolipoprotein B. In vitro experiments on MCF-7 breast cancer cells treated with atorvastatin were performed for comparison on the cellular level. Results: In the trial, 42 patients completed all study parts. From the paired tumor tissue samples, assessment of the cholesterol levels was achievable for 14 tumors, and for the LDLR expression in 24 tumors.
    [Show full text]
  • Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease
    International Journal of Molecular Sciences Review Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease Stanislav Kotlyarov Department of Nursing, Ryazan State Medical University, 390026 Ryazan, Russia; [email protected] Abstract: Chronic obstructive pulmonary disease (COPD) is the important medical and social problem. According to modern concepts, COPD is a chronic inflammatory disease, macrophages play a key role in its pathogenesis. Macrophages are heterogeneous in their functions, which is largely determined by their immunometabolic profile, as well as the features of lipid homeostasis, in which the ATP binding cassette transporter A1 (ABCA1) plays an essential role. The objective of this work is the analysis of the ABCA1 protein participation and the function of reverse cholesterol transport in the pathogenesis of COPD. The expression of the ABCA1 gene in lung tissues takes the second place after the liver, which indicates the important role of the carrier in lung function. The participation of the transporter in the development of COPD consists in provision of lipid metabolism, regulation of inflammation, phagocytosis, and apoptosis. Violation of the processes in which ABCA1 is involved may be a part of the pathophysiological mechanisms, leading to the formation of a heterogeneous clinical course of the disease. Keywords: chronic obstructive pulmonary disease; COPD; inflammation; ABCA1; reverse cholesterol transport; innate immune system Citation: Kotlyarov, S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive 1. Introduction Pulmonary Disease. Int. J. Mol. Sci. Chronic obstructive pulmonary disease (COPD) is one of the most widespread dis- 2021, 22, 3334. https://doi.org/ eases, it has great medical significance due to the high frequency of temporary and per- 10.3390/ijms22073334 sistent disability and mortality.
    [Show full text]
  • 1 CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on A
    Page 1 of 55 Diabetes CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet Lin Zhu1,2, Thao Luu2, Christopher H. Emfinger1,2, Bryan A Parks5, Jeanne Shi2,7, Elijah Trefts3, Fenghua Zeng4, Zsuzsanna Kuklenyik5, Raymond C. Harris4, David H. Wasserman3, Sergio Fazio6 and John M. Stafford1,2,3,* 1VA Tennessee Valley Healthcare System, 2Division of Diabetes, Endocrinology, & Metabolism, 3Department of Molecular Physiology and Biophysics, 4Devision of Nephrology and Hypertension, Vanderbilt University School of Medicine. 5Division of Laboratory Sciences, Centers for Disease Control and Prevention. 6The Center for Preventive Cardiology at the Knight Cardiovascular Institute, Oregon Health & Science University. 7Trinity College of Art and Science, Duke University. * Address correspondence and request for reprints to: John. M. Stafford, 7445D Medical Research Building IV, Nashville, TN 37232-0475, phone (615) 936-6113, fax (615) 936- 1667 Email: [email protected] Running Title: CETP inhibition and insulin resistance Word Count: 5439 Figures: 7 Tables: 1 1 Diabetes Publish Ahead of Print, published online September 13, 2018 Diabetes Page 2 of 55 Abstract In clinical trials inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels but doesn’t robustly improve cardiovascular outcomes. About 2/3 of trial participants were obese. Lower plasma CETP activity is associated with increased cardiovascular risk in human studies, and protective aspects of CETP have been observed in mice fed a high-fat diet (HFD) with regard to metabolic outcomes. To define if CETP inhibition has different effects depending on the presence of obesity, we performed short- term anacetrapib treatment in chow- and HFD-fed CETP-transgenic mice.
    [Show full text]
  • An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma
    Cleveland State University EngagedScholarship@CSU Mathematics Faculty Publications Mathematics Department 2-1-2014 An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma Ying Huang Cleveland Clinic Joseph A. DiDonato Cleveland State University, [email protected] Bruce S. Levison Cleveland Clinic Dave Schmitt Cleveland Clinic Lin Li Cleveland Clinic Follow this and additional works at: https://engagedscholarship.csuohio.edu/scimath_facpub Part of the Mathematics Commons See next page for additional authors How does access to this work benefit ou?y Let us know! Repository Citation Huang, Ying; DiDonato, Joseph A.; Levison, Bruce S.; Schmitt, Dave; Li, Lin; Wu, Yuping; Buffa, Jennifer; Kim, Timothy; Gerstenecker, Gary S.; Gu, Xiaodong; Kadiyala, Chandra S.; Wang, Zeneng; Culley, Miranda K.; Hazen, Jennie E.; DiDonato, Anthony J.; Fu, Xiaoming; Berisha, Stela Z.; Peng, Daoquan; Nguyen, Truc T.; Liang, Shaohong; Chuang, Chia-Chi; Cho, Leslie; PLow, Edward F.; Fox, Paul L.; Gogonea, Valentin; Tang, W.H. Wilson; Parks, John S.; Fisher, Edward A.; Smith, Jonathan D.; and Hazen, Stanley L., "An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma" (2014). Mathematics Faculty Publications. 161. https://engagedscholarship.csuohio.edu/scimath_facpub/161 This Article is brought to you for free and open access by the Mathematics Department at EngagedScholarship@CSU. It has been accepted for inclusion in Mathematics Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact [email protected]. Authors Ying Huang, Joseph A. DiDonato, Bruce S. Levison, Dave Schmitt, Lin Li, Yuping Wu, Jennifer Buffa, Timothy Kim, Gary S. Gerstenecker, Xiaodong Gu, Chandra S. Kadiyala, Zeneng Wang, Miranda K. Culley, Jennie E.
    [Show full text]
  • Abstracts from the 50Th European Society of Human Genetics Conference: Electronic Posters
    European Journal of Human Genetics (2019) 26:820–1023 https://doi.org/10.1038/s41431-018-0248-6 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Electronic Posters Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their abstract and to declare any competing financial interests. These disclosures are listed at the end of each abstract. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". 1234567890();,: 1234567890();,: E-P01 Reproductive Genetics/Prenatal and fetal echocardiography. The molecular karyotyping Genetics revealed a gain in 8p11.22-p23.1 region with a size of 27.2 Mb containing 122 OMIM gene and a loss in 8p23.1- E-P01.02 p23.3 region with a size of 6.8 Mb containing 15 OMIM Prenatal diagnosis in a case of 8p inverted gene. The findings were correlated with 8p inverted dupli- duplication deletion syndrome cation deletion syndrome. Conclusion: Our study empha- sizes the importance of using additional molecular O¨. Kırbıyık, K. M. Erdog˘an, O¨.O¨zer Kaya, B. O¨zyılmaz, cytogenetic methods in clinical follow-up of complex Y.
    [Show full text]
  • Steroid Sulfatase of Human Leukocytes and Epidermis and the Diagnosis of Recessive X-Linked Ichthyosis
    Steroid sulfatase of human leukocytes and epidermis and the diagnosis of recessive X-linked ichthyosis. E H Epstein Jr, M E Leventhal J Clin Invest. 1981;67(5):1257-1262. https://doi.org/10.1172/JCI110153. Research Article Patients with recessive X-linked ichthyosis, one of the inherited types of excessive stratum corneum cohesion, have deficient steroid sulfatase in fibroblasts grown from their dermis. Because of the expense and long period required to grow such cells, we have assayed this enzyme in peripheral blood leukocytes and found it to be undetectable in those from patients with this type of ichthyosis, but normal in those from patients with other hereditary or acquired types of ichthyosis. In addition, steroid sulfatase activity is less in leukocytes from women who are carriers of this disease than normal women, and this assay can be used to detect such carriers. Despite previous studies demonstrating that the gene for this enzyme escapes the inactivation of other x-chromosome genes, normal women have leukocyte steroid sulfatase activity only 1.3 times that of normal men, suggesting that some gene dosage compensation occurs. Normal human epidermis, the tissue most affected clinically, also expresses steroid sulfatase activity. The epidermal enzyme is similar in its subcellular localization, its molecular size, and kinetically to that of placenta, leukocytes, and fibroblasts. Find the latest version: https://jci.me/110153/pdf Steroid Sulfatase of Human Leukocytes and Epidermis and the Diagnosis of Recessive X-linked Ichthyosis ERVIN H. EPSTEIN, JR., and MARY E. LEVENTHAL, Dermatology Unit of the Medical Service, San Francisco General Hospital Medical Center, Department of Dermatology, University of California, San Francisco, California 94110 A B S T R A C T Patients with recessive X-linked pearance especially on the side of the neck, and the ichthyosis, one of the inherited types of excessive subsequently described comeal stippling (2).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and Is a Therapeutic Target for Advanced Prostate Cancer
    Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer Cameron M. Armstrong1*, Chengfei Liu1*, Liangren Liu1,2*, Joy C. Yang1, Wei Lou1, Ruining Zhao1,3, Shu Ning1, Alan P. Lombard1, Jinge Zhao1, Leandro S D'Abronzo1, Christopher P. Evans1,4, Pui-Kai Li5, Allen C. Gao1, 4, 6,7 Running title: Targeting steroid sulfatase for advanced prostate cancer Key words: Prostate cancer, steroid sulfatase, resistance, intracrine androgen synthesis, adrenal androgens 1Department of Urologic Surgery, University of California Davis, CA, USA 2Present address: Department of Urology, West China Hospital, Sichuan University, China 3Present address: Department of Urology, General Hospital of Ningxia Medical University, China 4UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA 5Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA 6VA Northern California Health Care System, Sacramento, CA, USA 7Corresponding author: Allen Gao, University of California Davis, 4645 2nd Avenue, Sacramento, CA 95817, USA. Phone: 916-734-8718, email: [email protected] *These authors contributed equally to the work. Conflict of interest: PKL and ACG are co-inventors of a patent application of the selected small molecule inhibitors of steroid sulfatase. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/1078-0432.CCR-20-1682 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]